Alumis Reports Q3 2026 Financial Results; LUMUS Phase 2b Trial in SLE Missed Primary Endpoint in Overall Population
Alumis reported Q3 2026 net loss of $94.9 million versus net loss of $110.8 million in Q3 2025, as R&D expenses declined to $80.8 million from $97.8 million. Revenue was $1.9 million, down slightly from $2.1 million in the prior-year quarter. The Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) did not meet primary or secondary endpoints in the overall trial population, though robust clinical responses were observed in a prespecified subgroup of patients with high interferon gene sig...
Forward guidance
Key takeaways
Net loss narrowed to $94.9 million in Q3 2026 from $110.8 million in Q3 2025, driven by lower R&D spending as the pivotal Phase 3 ONWARD1 and ONWARD2 trials completed.
Revenue declined to $1.9 million from $2.1 million, reflecting collaboration revenue from the Kaken Pharmaceutical agreement.
LUMUS Phase 2b trial in SLE missed primary endpoint in overall population but showed positive results in IFNGS-high subgroup, which represents the majority of moderate-to-severe SLE cases.
Cash, cash equivalents and marketable securities totaled $431.3 million as of September 30, 2026, sufficient to fund operations into Q4 2027.
Company remains on track to submit NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.
Phase 2 two-year safety data for envudeucitinib expected in Q4 2026.
Key metrics
Disclosure changes
- Clinical trial results
Phase 2b LUMUS trial of envudeucitinib for SLE did not meet primary and secondary endpoints in the overall trial population; robust clinical responses observed in prespecified IFNGS-high subgroup including on BICLA, CLASI-50, SRI-4, and LLDAS endpoints.
LUMUS missed overall population endpoints but IFNGS-high subgroup showed positive results; IFNGS-high patients represent majority of moderate-to-severe SLE cases but were under-represented in trial - Intangible assets impairment
Nine months ended September 30, 2026 includes $41.8 million intangible assets impairment loss; no impairment in Q3 2026
Material impairment charge of $41.8 million recorded in nine months 2026 related to intangible assets
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow ALMS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.